AGRX — Agile Therapeutics Balance Sheet
0.000.00%
- $10.43m
- $7.58m
- $19.59m
- 48
- 46
- 70
- 54
Annual balance sheet for Agile Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 34.5 | 54.5 | 19.1 | 5.25 | 2.56 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 0.865 | 1.53 | 3.38 | 3.39 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 35.3 | 56.8 | 23.9 | 11.4 | 9.53 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 14.2 | 14.4 | 13.4 | 0.872 | 0.487 |
| Other Long Term Assets | |||||
| Total Assets | 49.5 | 73.1 | 39.3 | 14.2 | 10.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 3.79 | 7.35 | 29.3 | 13.4 | 20.8 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.79 | 23.7 | 30.1 | 19.8 | 26.6 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 45.7 | 49.3 | 9.27 | -5.54 | -16.3 |
| Total Liabilities & Shareholders' Equity | 49.5 | 73.1 | 39.3 | 14.2 | 10.3 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |